CEO and founder Wayne Paterson discussed the company’s DurAVR transcatheter aortic valve replacement (TAVR) program, recent ...
Emboline expects that its technology designed to reduce stroke risk during structural heart procedures will launch in the US and Europe later this year.
一些您可能无法访问的结果已被隐去。
显示无法访问的结果